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Key Points
• This article defines ele-
ments of adult sickle
cell centers to facilitate
care and alleviate health
disparities in this patient
group.
•Models of SCD care
were developed and
disseminated during
a workshop to train
health care professio-
nals to establish SCD
clinical centers.
Sickle cell disease (SCD) is themost common inherited blood disorder in theUnited States. It is
amedically and socially complex, multisystem illness that affects individuals throughout the
lifespan. Given improvements in care, most children with SCD survive into adulthood.
However, access to adult sickle cell care is poor inmanyparts of theUnited States, resulting in
increased acute care utilization, disjointed care delivery, and early mortality for patients.
A dearth of nonmalignant hematology providers, the lack of a national SCD registry, and
the absence of a centralized infrastructure to facilitate comparative quality assessment
compounds these issues. As part of a workshop designed to train health care professionals in
the skills necessary to establish clinical centers focused on the management of adults living
with SCD, we defined an SCD center, elucidated required elements of a comprehensive adult
SCD center, and discussed different models of care. There are also important economic
impacts of these centers at an institutional and health system level. As more clinicians are
trained in providing adult-focused SCD care, center designation will enhance the ability to
undertake quality improvement and compare outcomes between SCD centers. Activities
will include an assessment of the clinical effectiveness of expanded access to care, the
implementation of SCD guidelines, and the efficacy of newly approved targetedmedications.
Details of this effort are provided.
Introduction
Sickle cell disease (SCD) is the most common inherited hemoglobinopathy in the United States,
affecting ;100 000 individuals. Improvements in childhood mortality attributed to universal
newborn screening, antipneumococcal vaccination, antibiotic prophylaxis, and disease-specific
treatments (eg, blood transfusion and hydroxyurea) have allowed ;96% of children with SCD to
reach adulthood.1 Approximately 60% of the SCD population in the United States is now above the
age of 18 years.2
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Although most individuals with SCD living in resource-rich countries
live into their fifth decade, the burden of illness remains high.3
Excess morbidity and mortality is tied to higher acute care utilization,
hospitalization, and readmission rates,1,4,5 especially among patients
18 to 30 years of age.6 A recent modeling study showed a lower
projected life expectancy (54 vs 76 years) and quality-adjusted life
expectancy (33 vs 67 years) for individuals with SCD relative to
those without SCD.7 Data from California are even more concern-
ing: recent estimates put the mean age at death at 43 years for
women and 41 years for men with SCD.8
Adults living with SCD are often medically and socially complex
and experience significant health disparities.9 These individuals
face multiple hurdles to attaining high-quality and continuous care
across the lifespan. Upon entering adulthood, patients often lose
their primary medical home and health insurance. Historically, SCD
was considered a pediatric disease and many adult-focused
providers have not received training in its care. Adult patients suffer
from a shortage of specialized, knowledgeable providers and
difficulties in care coordination between primary and subspecialty
services.10,11 In contrast, hemophilia and cystic fibrosis, which each
have a population incidence of less than one-half that of SCD
in the United States, benefit from .130 comprehensive treatment
centers nationwide.9 Furthermore, both conditions have national
registries and funding for clinical centers to support their populations
whereas SCD does not. For some patients with SCD, especially in
low-income and rural communities, the lack of specialized providers
and comprehensive care is severe.12,13
The need for comprehensive SCD care has long been recognized,
as reflected by the passage of the National Sickle Cell Disease
Control Act in 1972. This fueled a National Heart, Lung, and Blood
Institute (NHLBI) initiative to create SCD centers with the triple
directive of simultaneously embarking upon research, comprehen-
sive care, and engagement with community-based organizations
(CBOs) primarily focused on children. This initiative was highly
effective at reducing pediatric mortality through newborn screening
and penicillin prophylaxis. Unfortunately, funding was not sustained
and the centers closed. Although much of the pediatric care was
absorbed by academic pediatric hematology-oncology centers, the
same is not true for affected adults. Improved access to adult
comprehensive SCD care is still a critical need.14
The benefits of adult comprehensive SCD programs include better
health outcomes such as fewer acute care visits and hospital-
izations. These improvements are anticipated to improve quality
of life and result in greater cost-effectiveness as compared with
episodic, emergency department (ED)-based care.15-18 Patients
with SCD treated at SCD centers use ED and inpatient facilities
less frequently, have decreased health care costs overall,15,16,19
and are more likely to be prescribed hydroxyurea,20 which has been
demonstrated to improve psychosocial outcomes including health-
related quality of life.21
Comprehensive care of SCD requires that affected individuals have
a continual bidirectional relationship with their medical team.
However, many patients are living in areas in which SCD-focused
providers are unavailable (Figure 1). As a result, internists and
primary care physicians (PCPs) have been left to provide the
majority of SCD care in an acute pain-based or episodic illness-
based model. These providers may have limited experience in the
care of individuals with SCD and may not keep abreast of SCD
guidelines.22 In a survey of family physicians in the United States
and Canada, only 20% said they feel comfortable treating patients
with SCD.23,24 Thus, without a comprehensive center, affected
adults rely on acute care services, often resulting in suboptimal
clinical outcomes and extracting a heavy psychological price on the
individual.12
Models of comprehensive, team-based management focused on
care coordination have demonstrated efficacy in other inherited
conditions.25,26 New medications for SCD (eg, crizanlizumab and
voxelotor) offer hope for improved outcomes. These medications
are promising, but the benefits of any new SCD therapies will not be
fully recognized in places where health care access is highly
fragmented and specialist care is lacking. Furthermore, these novel
medications will not supplant the need for regular comprehensive
care.27 Even implementation of current therapies (hydroxyurea, iron
chelation) has been limited by lack of access to specialized care.
In 2016, the American Society of Hematology (ASH) launched the
Sickle Cell Disease Initiative as their first disease-specific initiative
to improve outcomes for people living with SCD in the United
States and globally. Elements of this multifaceted initiative include
the development of clinical practice guidelines, the launch of
a clinical trials network, and the development of a research data hub
to capture real-world evidence on patient care. ASH has also
complemented these efforts with programs to increase access to
care, including advocacy for payment reform and increased provider
education.
Specifically recognizing deficiencies in the provision of health care
services for adults with SCD, ASH launched an effort to increase
the number of adult SCD care programs. Cochairs of this initiative
were selected based on their demonstrated success in developing
SCD centers and interest in improving access to care. Goals of this
effort include increased access for adults to SCD-specific services
(infusion centers, appropriate care in ED, etc), transition from
pediatric to adult care, and access to the other care profes-
sionals needed to address the medical and social aspects of
living with SCD.
Methods
Todefine themost important elements of anSCDcenter, a convenience
sample of 14 established adult SCD treatment centers in the United
States and the United Kingdom was sent, via e-mail, a qualitative
survey with several questions. The survey was directed toward the
leading physician(s) in each center. The first questions asked that
each center be defined, including the patient population, staffing,
clinic structure, care provision, and outreach efforts, followed by
a list of components for assignment into tiers as either (1) essential
elements of a sickle cell center (components needed to define
themselves as a “sickle cell center”), (2) optimal (but not necessary/
essential), or (3) those elements that could be considered
suggested (services that improve care delivery but are not essential
to provide guideline-based care). Importantly, participants were not
asked to include information on their centers’ research capacity or
relationship with outside CBOs. The focus of the survey was
specific to patient care delivery as an SCD center.
Recognizing that the United States is just 1 of many countries
treating SCD, inclusion of non-US–based systems was considered
important. However, to be consistent with the goals of the survey,
only Canadian and UK clinics were included as they have payer
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systems that seek to optimize cost-effectiveness similar to the
United States. Although their health systems are 1-payer systems,
they were felt to be more similar to the United States than the
French or Italian payer systems.
The questions included in the survey and the list of potential
components of sickle cell centers were composed by the ASH
workshop cochairs as we created the workshop. In addition, we
considered the requirements of SCD centers per available
regulations, including NHLBI SCD guidelines, the UK Forum on
Quality Services for Health Services for People with Haemoglobin
Disorders, and the Joint Accreditation Commission for Health Care
Organizations (JACHO).28,29 Finally, we reviewed the essential
qualities of a hemophilia treatment center and included those concepts
in the models of care.30 Components listed for categorization
included: sickle cell specialist, social worker, case manager,
dedicated nurse/nursing staff, advanced care providers, mental
health specialist (psychologist or other), PCP, physical therapist,
pharmacist, dedicated clinic space or location, infusion center/day
hospital/observation unit, and defined business plan. Respondents
could also add other components not included in the list that they
felt were needed/necessary.
Consensus was defined as at least 75% of respondents agreeing to
the placement of components as essential, optimal, or suggested.
If a component was only recommended by 1 or 2 physicians, it
was immediately placed in the “suggested” category. If there were
components that were between categories, another e-mail was sent
to ask for sites to choose 1 or the other categories in order to
achieve consensus.
Elements that all of the centers classified as “essential” reached
consensus easily among center physicians. Other elements that did
not reach majority were categorized as “optimal” or “suggested” as
described earlier in “Methods.”
Results
Consensus-defined essential components of an
SCD center
Comprehensive SCD care requires a programmatic, multidisci-
plinary, team-based approach. Survey respondents unanimously
agreed that all adult SCD centers must offer comprehensive,
evidence-based care for adults with SCD that is coordinated
throughout the institution. The SCD center should also be the
recognized authority (leader within their larger hospital or academic
center) for managing SCD as a patient population within their
institution/organization. The required and suggested center ele-
ments were defined as described herein by the survey participants
(Figure 2).
At a minimum, an adult SCD center requires a physician lead who is
considered a specialist in the care of individuals living with SCD.
This individual will accept responsibility for establishing protocols
for care, training, implementing audits, and sharing in the overall
responsibility for the management of the clinic. The lead SCD
specialist should be comfortable providing evidence-based pain
management, should undertake continuing professional develop-
ment of relevance to this role, and have an established plan for how
to cover for absences.
Other required elements include 1 or more social workers, a patient
coordinator (sometimes called a patient navigator or case manager),
and dedicated nursing staff, as well as the ability to offer acute and
chronic pain management, transfusions (including apheresis), and
timely access to specialist services.
Optimal elements that a center may include are a lead nurse/clinic
manager who could also serve as the center director or codirector
with the SCD specialist. This person helps share responsibility







Figure 1. Estimated number of individuals with
SCD, based on state-specific African American and
Hispanic birth-cohort disease prevalence and 2008
US census population, corrected for early mortality.
Reprinted from Hassell49 with permission from Elsevier.
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protocols as well as training and audits related to the center. The
clinic manager can have additional responsibilities including quality
improvement and oversight.
Although not essential for sickle cell centers, having dedicated
infusion space or a day hospital is optimal. Multiple studies have
demonstrated the utility of a day hospital to decrease ED care and
provide SCD-specific care in a timely manner (especially during
pain crisis).31,32 Sickle cell centers also need readily accessible
behavioral health staff. Although those surveyed did not feel that
having a dedicated psychologist was a “must,” there was universal
agreement that it is preferred. Optimal elements also include
a transition plan for helping children adapt and transfer to the adult
care setting, and available access to a gynecology provider or other
means of providing contraception for women with SCD.
In addition to these elements, several other components are
considered adjunct (preferred but not strictly necessary). These
include a primary care provider (in an embedded model), a physical
and occupational therapist, a pharmacist, accessible dental care (as
may be available hemophilia treatment centers), and an SCD
educator. Also considered adjunct but preferred is a dedicated
clinical space and staff that are not shared with other patient
populations.
Models of SCD adult care
The centers surveyed were also categorized into different models
defined based on the size of the center, patient population,
structure (within a division or department), services provided
(whether they had primary care within the SCD center), and
staffing for care delivery (Figure 3). These models were also defined
by their location of services and whether they are stand-alone clinics
or embedded within other divisions/departments/clinics.
Classic comprehensive care model. The classic compre-
hensive care model provides coordinated, team-based SCD care
using dedicated clinical space and staff. This type of center is more
likely found in urban locations within larger hospital systems or
academic centers. These centers usually provide care to a local,
relatively large urban SCD population.
A comprehensive clinic will be led by a sickle cell specialist who
is supported by a team of advanced practice providers (APPs):
advanced nurse practitioners or physician assistants, a social
worker, and others focused on this patient population. Facilities
usually include an infusion center/day hospital to provide acute care
and/or transfusion management. Centers in which an infusion
center is not available have prespecified individualized care plans
and designated treatment locations for acute management.
By definition, these centers must have ready access to radiology,
laboratory services, apheresis, and a blood bank, as well as other
disciplines needed in the care of individuals with SCD (Table 1).
Most will develop plans and protocols for comanagement with
PCPs and other services with a focus on providing team-based,
care coordination.
Example. The Sickle Cell Center for Adults at Johns Hopkins
Medicine provides comprehensive services for persons with SCD
who live in the greater metropolitan Baltimore, MD andWashington,
DC areas. The center offers regularly scheduled outpatient visits,
hydroxyurea and transfusion management, genetic counseling, pain
management, education, and referral to subspecialty and social
services. The center employs full-time hematologists, nurses, APPs,
and staff devoted to the care of persons with SCD. Importantly, the
center is well embedded within the larger Johns Hopkins Medicine
community and staff have established relationships with other
departments, notably the ED, which facilitates timely assessments
of patients with acute needs. The dedicated clinic space also
includes a day hospital for acute pain management.
The infusion center at Johns Hopkins has significantly reduced
the admission rate from their ED and 30-day readmissions.15
Community-level impact has also been noted, with a statistically
significant 7% annual decrease in the likelihood of readmissions for
hospitals in the city of Baltimore.
Embedded care model. In institutions serving fewer patients
with SCD or without enough dedicated space and staff, an
embedded SCD care center can provision care by “embedding”
itself within a larger, more financially feasible care program and
sharing resources. Given the abundance of comprehensive cancer
centers and the synergies and similarities between operational
infrastructure, several adult SCD programs have formally embed-
ded themselves within hospital-based cancer centers.
In an embedded center, clinical space can be shared between
programs, improving efficiency and reducing costs. Personnel can
also be shared provided that coordinated, team-based care of SCD
patients, who are likely to be far fewer in number than the other
patients, can be ensured. These programs still require the leader-
ship of a sickle cell specialist, but supporting physicians and APPs
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Figure 2. Elements of an adult sickle cell center. Required elements represent
the minimal components necessary for a functional and effective comprehensive
adult sickle cell center. Optimal elements reflect valuable resources that may be
included as part of an adult sickle cell center, although they are not essential.
Adjunct elements serve as a supplement to the required and optimal elements and
are considered preferred but not strictly necessary.
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In the case of a shared benign hematology/heme-onc model,
nursing staff can be shared with hematology-oncology services.
Physicians who have sufficient knowledge of SCD management
can assist in patient care and provide support to the program. As
with the classic comprehensive SCD center model, these centers
must offer access to radiology, laboratory services, apheresis, and
a blood bank, along with other disciplines needed in the care of
individuals with SCD. (Table 1). Embedded centers should also have
plans and protocols for comanagement with primary care and other
services with a focus on providing team-based, patient-centered care.







Urban areas Urban areas Urban and suburban
areas
Rural areas
Led by SCD specialist
Designated facilities usually
include an infusion center/day
hospital for treatment of vaso-
occlusive pain crises and/or
transfusion management
Led by SCD specialist, but
supporting physicians and APPs
with SCD knowledge who can be
shared with the primary program
Model may include an infusion
center or day hospital, but must
have defined plans/protocols for
the provision of acute care/pain
management
Full-service care center with
secondary establishments
offering limited services
Hub is led by
SCD specialist
Anchored by an established, full-
service center (hub) and
complemented by secondary, more
remote ‘spokes’ offering more
limited services.
Spokes may be run by PCPs
or APPs with specialty SCD
training and have limited
clinics space, or share infusion
beds with other programs.
Spokes should have telehealth





networked system of care
Network of Clinical Staff
Patients who prefer to maintain a
primary care relationship outside
medical home can still receive








E.g. Nursing staff can be
shared with oncology or
hematology-oncology services.
Plans/protocols in place for
co-management with primary
care and other services




workers, and others focused on
this patient population.
All models afford ready access to radiology, laboratory services, apheresis,
a blood bank, as well as other disciplines needed in the care of individuals






















Medical Home Hub and Spoke
Figure 3. Overview of adult SCD care models. The 4 models of adult SCD care differ with respect to the clinical space and resources, staffing of sickle cell specialists and
APPs, the developed environments to which the model is most suited, and other similar factors.
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Example. A retrospective analysis of a new adult SCD center
embedded within an existing cancer center at the University of
Connecticut Health Center demonstrated that this strategy in-
creased the number of annual outpatient preventative visits for
chronic disease management, reduced hospitalization rates and
length of stay, and decreased hospitalization for management of
acute pain.33 Hydroxyurea use among eligible patients increased
from 30% before the establishment of the embedded center to
90% after 5 years, indicating that access to dedicated specialist
care was likely an important barrier for provision of established
treatments. Importantly, the sickle cell program became a regional
referral center for adults with SCD. This program was ultimately able
to garner substantial hospital resources to transition into a classic
comprehensive care model with dedicated space and staffing.
Specialized medical home model. The medical home con-
cept is a primary care construct traditionally defined as a center for
providing patient-centered, team-based, accessible comprehensive
care with a focus on quality and safety. The medical home model
of care was designed to meet the complexities of chronic disease
with care coordination going through a central PCP who acts
as a team lead or quarterback.34 Evidence of the benefits of the
medical home on quality and costs have been mixed.35
The defining characteristic of a sickle cell–specialized medical
home is the colocation of primary care within the comprehensive
sickle cell care structure. Like a classic comprehensive center,
a SCD specialized medical home will have dedicated clinical staff
and space, along with a designated care coordinator. In this setting,
the lead sickle cell specialist acts as the team leader but the care is
collaborative and delivered simultaneously. This model may or may
not include an infusion center or day hospital, but must have defined
plans for the provision of acute care/pain management. This model
can be considered in both urban and suburban settings, but is
unlikely to have enough patients in its catchment area for financial
feasibility in rural locations. However, when patients present from
farther afield, the opportunity to have all of their medical needs
accommodated in 1 place is of value. Patients who prefer to
maintain a PCP relationship outside of the medical home can still
receive SCD care at the specialty center. As with the other models
of care, these centers must have access to radiology, laboratory
services, apheresis, a blood bank, and other services needed for the
care of individuals with SCD (Table 1).
Example. The Lifespan Comprehensive Sickle Cell Center at
the Medical University of South Carolina (MUSC) provided both
specialized sickle cell care and primary care for affected adults from
2014 to 2018. Patients seen at the center were able to see both
providers at each visit; an attached infusion center allowed for acute
care visits, including transfusion management and pain medications
for acute crises.
Over 400 adults with SCD were followed longitudinally by the
Lifespan center at MUSC. Just over one-half of patients (55%)
opted to receive their primary care at the center, primarily for ease of
scheduling and coordinated communication. At program entry, the
majority of these individuals had not seen a PCP in the previous
12 months (J.K., unpublished observational data, MUSC years
2014-2019). For the 45% of patients who preferred to continue
seeing their “outside” PCP, only SCD-specific care was provided at
Lifespan. To assess the effectiveness of the program, a group of
27 Medicare-identified accountable care organization patients were
identified retrospectively. Only those followed consistently from
2015 to 2017 were included in the analysis. These individuals saw
a 65% decrease in ED visits and a 46.5% decrease in hospital-
izations (J.K., unpublished observational data, MUSC years 2014-
2019).
Another example of a specialized medical home model is The
Adult Comprehensive Sickle Cell Center at The Ohio State
University (Columbus, OH). This program has partnered with the
internal medicine physicians at the medical center to provide in-
house–based primary care to over 40 patients. The internal
medicine provider visits the patient at home to allow for longer,
more comprehensive evaluations of the patients’ health and needs.
In conjunction with their SCD care within the comprehensive
center, these individuals received their primary care. In addition to
improved SCD outcomes, this program has demonstrated improve-
ments in primary care outcomes, including immunization rates and
cancer-screening rates. Additionally, since the program started,
admissions, readmissions, and total number of hospital days have
decreased, along with a modest decrease in ED utilization.
Hub-and-spokemodel. Individuals with SCD living in rural areas
are more likely than their urban counterparts to lack comprehensive
coordinated care. These patients have higher rates of acute care
utilization and readmission,36 and greater dissatisfaction with the
care received, often related to the longer wait times in rural EDs.37
Even living farther from an established urban sickle center, but still
within its catchment area, can adversely impact care.38,39 Tele-
medicine and telementoring have been proposed as ways of
extending care from urban centers to rural regions.40,41
The term “hub and spoke” offers a vivid image of how this model can
expand access to care. The hub-and-spoke design provides
a networked system of care anchored by an established, full-
service care center (hub) complemented by secondary establish-
ments (spokes) that offer more limited services, but alleviate acute
shortages in care. As an organizational design, hub and spoke is
Table 1. SCD complications and specialists needed
Complication Specialists ES or P
Retinopathy Retinal specialist ES
Leg ulcer Wound care ES
Restrictive lung disease Pulmonary ES
Pulmonary hypertension Cardiology (or pulmonary)* ES
Renal disease Nephrology ES
AVN Orthopedics ES
Gallstones/hypersplenism General surgeon ES
Mood disorders Psychiatry/psychology ES
Neurovascular disease Neurosurgeon ES
Priapism Urology ES
Transfusion-related complications Blood bank specialist ES
Pregnancy-related complications Maternal-fetal medicine/high-risk OBGYN ES
Iron overload (assessment) Radiologic specialists P
Chronic pain Pain specialist P
AVN, avascular necrosis; ES, essential; OBGYN, obstetrics and gynecology specialist; P,
preferred.
*Prefer (not essential) with sickle cell–specific training.
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readily scalable and can operate efficiently with the replication of
operations across multiple sites.42 A basic example is a health care
network that consists of a main campus and 1 or more satellite
campuses.
Centers designed according to any of the care models mentioned
(the classic comprehensive, the embedded, or the specialized
medical home) could serve as the central hub from which spokes
extend to provide care to geographically distant areas. As previous
discussed, the hub will be led by a sickle cell specialist and have
ready access to all necessary subspecialists. Spokes may be run by
PCPs with contacts to the hub or by APPs with specialty training in
SCD management. These spokes may have dedicated infusion
areas, but are more likely to share infusion space. Spokes must be
able to provide transfusion and infusion services on the same
campus. Spokes should also have telehealth capabilities with
the hub, and established protocols for comanagement and the
management of acute pain and emergencies. An advantage of this
model is the potential to extend care to areas remote from a larger
SCD care center at lower cost.
Example. The Lifespan Comprehensive Sickle Cell Clinic at
MUSC serves as a “hub” for the hub-and-spokes state network,
called (SC).2 The (SC)2 network includes spokes throughout South
Carolina in Beaufort, Columbia, and Georgetown. The Beaufort
Memorial Hospital (BMH) is 1 of the spokes of the network. The
SCD clinic at BMH is run by a full-time APP (a nurse practitioner)
who trained with the hub prior to the opening of the spoke. The
spoke clinic provides care Monday through Friday and serves 40
individuals with SCD in the Beaufort area. The clinic offers transfusion
therapy, hydroxyurea management, and acute pain management with
individualized care plans, and has local, emergency backup from the
ED and the hospitalist service. This spoke clinic provides care under
the supervision of the “hub” provider, checking in as needed on
patient care issues. The supervising SCD provider from the hub
uses telemedicine to see patients remotely, both on a scheduled
and as-needed basis, and travels to assess patients at their home
spoke clinics on a quarterly basis. These in-person clinics also
provide the SCD specialist provider an opportunity to assess new
patients.
Economic aspects of an SCD center
Improving access to regular and expert care for individuals with
SCD can be a financially advantageous strategy. Patients who lack
comprehensive management require more acute hospital care,
which is more expensive than the provision of comprehensive,
regular care.15,19 The charges associated with SCD care are
disproportionate to its prevalence and complexity. In 2006, there
were an estimated 188 194 ED visits among adults and 44188 ED
visits among children in the United States, with total charges
estimated to be $356 million dollars.43 Combined ED and inpatient
charges were estimated to be $2.4 billion dollars. Individuals with
SCD had 3 times the charges for hospitalization associated with an
ED visit (per 100 patients with the disease) compared with those
with congestive heart failure.43
Individuals treated in dedicated sickle cell day hospitals have fewer
ED visits, lower admission rates, and shorter hospital stays;
therefore, the potential exists for substantial overall savings for the
institution and the payer.15,31,44,45 Cost savings must be viewed
from several perspectives: patient, hospital system, and the payer.
The data support the premise that access to SCD-specific care and
outpatient infusion results in a decrease in hospital admissions.
Although the total cost differential is dependent on length of stay,
procedures, and tests ordered, etc, the decrease in hospital
admissions translates into overall less money spent on hospital-
related charges regardless of who is paying the bill.46 In 1 study,
3 years after opening a sickle cell unit, a 43% decrease in hospital
admissions was demonstrated along with a 49% decrease in
occupied bed days.44 In the third year of operation, 84% of patients
treated for pain episodes were managed without the need for
hospital admission. Although it is not clear that the hospital system
did not lose money that would have been reimbursed to them, it is
likely, based on other similar reports,47,48 that the cost, including
subsequent readmission costs, would have exceed the payer-
based diagnosis-related group funding, resulting in a loss for the
institution.
The ASH SCD Centers Workshop
In November 2019, ASH hosted its inaugural SCD Centers
Workshop, a 3-day in-person event held at ASH headquarters in
Washington, DC. The workshop was led by 4 cochairs who are all
directors of adult sickle cell treatment programs and who have
extensive experience in developing comprehensive adult treatment
centers. Additional faculty included those with backgrounds in
financial analysis, social work, and care coordination.
Applicants included clinical interprofessional teams seeking to
develop adult comprehensive care programs. Members of the
team included a clinical medical champion for the center (usually
a hematologist or general internist, but possibly an APP), business
officials from the institution, and additional interested health care
professionals.
Personnel from 11 institutions with nascent adult SCD programs
attended. The curriculum included didactics and small group
breakout sessions on a number of (nonclinical) requirements for
a SCD center, including how to obtain “buy-in” and financial
support from a health care institution, collaboration with SCD
stakeholders and their support organizations, and team building and
appropriate training for staff, including how to address potential
unconscious bias.
The workshop focused on explaining the core elements of a center,
as noted herein, and the ways in which care for affected adults can
be optimized. Attendees were assigned to a faculty member/mentor
from within their geographic region. Mentors and attendees met
multiple times throughout the 3-day workshop to identify the optimal
model for their center, strategize methods for refining their team,
and to begin writing their business plan. Over the next 12 months,
attendees will continue to be mentored in establishing sickle cell
centers.
Discussion
The designation of an SCD comprehensive center will create the
ability to standardize the implementation of SCD guidelines and
assess their impact on patient outcomes. These centers can also
work together to identify areas in which evidence is lacking.
Importantly, the infrastructure of center-based care will allow for
enhanced comparative quality and safety metrics as well as
cooperative, postapproval assessments of novel therapies. Center
designation will also codify, legitimize, and promote comprehensive
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sickle cell centers within their current hospital/academic environ-
ment and enhance the careers of current and future center
directors and staff (both locally and nationally).
Several features of currently established centers have not been
included in this description, notably the capacity for doing clinical
research and the need for relationships with sickle cell-focused
CBOs. The present project seeks to define and maintain centers
based on their ability to deliver quality, team-based, patient-
centered care that is economically sustainable. Although the hope
is that both new and established SCD centers will participate in
clinical research and engage with local CBOs, it is not considered
a requirement.
In conclusion, comprehensive care for individuals living with SCD is
a necessity. Essential elements are required for an SCD center to
provide team-based care. However, the model of care used can vary
according to location, personnel, the size of the population served,
and financial and institutional considerations. SCD centers for
adults must provide compassionate, comprehensive care that is
coordinated to ensure continuous and personalized care with
attention to both the physical and emotional well-being of the
individual. Providing standardized, equitable patient-centered man-
agement will ensure higher quality, more cost-effective care for this
vulnerable patient population.
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